Introduction: Venous (VTE) and arterial thromboembolic events are one of the most common complications in the Sars-Cov2 infection. Incidence of these complications ranges from 5% to 45%, as found among studies. Cancer is an established risk factor of thromboembolic events. However, it is not well known the incidence of thromboembolic events among cancer patients with COVID-19. Aim: To determine the incidence of venous and arterial thromboembolic complications between hospitalized cancer patients with covid-19. Materials and Methods: We performed a retrospective analysis of cancer patients with COVID-19 admitted to “Gregorio Marañón General University Hospital” from March to June 2020. Eligibility criteria required a positive polymerase chain reaction or IgG/IgM serology test for Sars-Cov2. The main objective is to obtain the incidence of thrombosis between hospitalized cancer patients with COVID-19. The secondary objective is to determine the mortality. Results: We included 79 patients, 64.6% male, with a mean age of 67.9 years old (range 31-94). The median follow-up of the patients was 110 days. Seventy-one patients (89.9%) had active cancer and 72.2% received oncology treatment in the previous 3 months. Sixty-six patients (83.5%) received therapeutic or prophylactic anticoagulation. Baseline characteristics of the patients are summarised in Table 1 overleaf. Five patients (6.3%) suffered a venous thrombosis, and no episodes of arterial thromboembolic events were reported at the end of the study. 3 patients (60%) developed a pulmonary embolism and 2 patients (40%) a deep venous thrombosis. Thirty patients died: 17 patients (56.7%) because of Covid-19, 10 patients (33.3%) due to tumour progression and 3 patients (10%) as a result of other causes. Mortality rate did not significantly differ among patients who developed thrombosis: 38% non-thrombosis vs 33.3% thrombosis;p=0.684. Conclusions: In our study the incidence of venous thromboembolic events among cancer patients with Covid-19 was found to be 6.3% and no arterial thromboembolic event was noticed. This figure is similar to the incidence reported in general population. Mortality was not higher among patients with thromboembolic events. (Table presented.)
PO-58 Venous and arterial tromboembolic events among hospitalized cancer patients with SARS-COV2 infection